Gao X , Feng J , Wei L , Dong P , Chen J , Zhang L , et al . Defensins: a novel weapon against Mycobacterium tuberculosis ? Int Immunopharmacol . 2024 ; 127 : 111383 .

Goossens SN , Sampson SL , Van Rie A . Mechanisms of drug‑induced tolerance in Mycobacterium tuberculosis . Clin Microbiol Rev . 2020 ; 34 ( 1 ): e00141 ‑ 20 .

Yang L , Zhuang L , Ye Z , Li L , Guan J , Gong W . Immunotherapy and bio‑markers in patients with lung cancer with tuberculosis: recent advances and future directions . iScience . 2023 ; 26 ( 10 ): 107881 .

Chandra P , Grigsby SJ , Philips JA . Immune evasion and provocation by Mycobacterium tuberculosis . Nat Rev Microbiol . 2022 ; 20 ( 12 ): 750 – 66 .

Zhuang L , Yang L , Li L , Ye Z , Gong W . Mycobacterium tuberculosis : immune response, biomarkers, and therapeutic intervention . Med‑Comm . 2024 ; 5 ( 1 ): e419 .

Kamboj D , Gupta P , Basil MV , Mohan A , Guleria R , Bhatnagar A , et al . Improved Mycobacterium tuberculosis clearance after the restoration of IFN‑γ + TNF‑α + CD4 + T cells: impact of PD‑1 inhibition in active tubercu‑losis patients . Eur J Immunol . 2020 ; 50 ( 5 ): 736 – 47 .

Li PH , Kong XY , He YZ , Liu Y , Peng X , Li ZH , et al . Recent developments in application of single‑cell RNA sequencing in the tumour immune microenvironment and cancer therapy . Mil Med Res . 2022 ; 9 ( 1 ): 52 .

Sharma A , Chakraborty A , Jaganathan BG . Review of the potential of mesenchymal stem cells for the treatment of infectious diseases . World J Stem Cells . 2021 ; 13 ( 6 ): 568 – 93 .

Cao X , Fu YX , Peng H . Promising cytokine adjuvants for enhancing tuberculosis vaccine immunity . Vaccines (Basel) . 2024 ; 12 ( 5 ): 477 .

Mi J , Liang Y , Liang J , Gong W , Wang S , Zhang J , et al . The research progress in immunotherapy of tuberculosis . Front Cell Infect Microbiol . 2021 ; 11 : 763591 .

Bo H , Moure UAE , Yang Y , Pan J , Li L , Wang M , et al . Mycobacterium tuberculosis ‑macrophage interaction: molecular updates . Front Cell Infect Microbiol . 2023 ; 13 : 1062963 .

Kim H , Shin SJ . Pathological and protective roles of dendritic cells in Mycobacterium tuberculosis infection: interaction between host immune responses and pathogen evasion . Front Cell Infect Microbiol . 2022 ; 12 : 891878 .

Qin Y , Xu J , Wang Q , Shi J . Cytotoxic granules and effector molecules from immune cells in tuberculosis: mechanisms of host defense and therapeutic potential . Virulence . 2025 ; 16 ( 1 ): 2542466 .

Sankar P , Mishra BB . Early innate cell interactions with Mycobacterium tuberculosis in protection and pathology of tuberculosis . Front Immu‑nol . 2023 ; 14 : 1260859 .

Scriba TJ , Maseeme M , Young C , Taylor L , Leslie AJ . Immunopathology in human tuberculosis . Sci Immunol . 2024 ; 9 ( 102 ): eado5951 .

Ogongo P , Tezera LB , Ardain A , Nhamoyebonde S , Ramsuran D , Singh A , et al . Tissue‑resident‑like CD4 + T cells secreting IL‑17 control Mycobacterium tuberculosis in the human lung . J Clin Investig . 2021 ; 131 ( 10 ): e142014 .

Carpenter SM , Lu LL . Leveraging antibody, B cell and Fc receptor interactions to understand heterogeneous immune responses in tuber‑culosis . Front Immunol . 2022 ; 13 : 830482 .

Bedard M , van der Niet S , Bernard EM , Babunovic G , Cheng TY , Aylan B , et al . A terpene nucleoside from M. tuberculosis induces lysosomal lipid storage in foamy macrophages . J Clin Investig . 2023 . https://doi.org/10.1172/JCI16 1944 .

Xander C , Rajagopalan S , Jr Jacobs WR , Braunstein M . The SapM phosphatase can arrest phagosome maturation in an ESX‑1 independ‑ent manner in Mycobacterium tuberculosis and BCG . Infect Immun . 2024 ; 92 ( 7 ): e0021724 .

Ramon‑Luing LA , Palacios Y , Ruiz A , Téllez‑Navarrete NA , Chavez‑Galan L . Virulence factors of Mycobacterium tuberculosis as modulators of cell death mechanisms . Pathogens . 2023 . https://doi.org/10.3390/pathogens12060839 .

Shariq M , Quadir N , Sharma N , Singh J , Sheikh JA , Khubaib M , et al . Mycobacterium tuberculosis RipA dampens TLR4‑mediated host protec‑tive response using a multi‑pronged approach involving autophagy, apoptosis, metabolic repurposing, and immune modulation . Front Immunol . 2021 ; 12 : 636644 .

Leyto SM , Digesa LE , Lakew S , Wondmagegn H , Mare KU , Hadaro TS , et al . Tuberculosis patients’ satisfaction with directly observed treat‑ment short course strategy and associated factors in Southern Ethiopia: a mixed method study . BMC Public Health . 2024 ; 24 ( 1 ): 2452 .

Stagg HR , Thompson JA , Lipman MCI , Sloan DJ , Flook M , Fielding KL . Forgiveness is the attribute of the strong: non‑adherence and regimen shortening in drug‑sensitive tuberculosis . Am J Respir Crit Care Med . 2023 ; 207 ( 2 ): 193 – 205 .

Trajman A , Campbell JR , Kunor T , Ruslami R , Amanullah F , Behr MA , et al . Tuberculosis . Lancet . 2025 ; 405 ( 10481 ): 850 – 66 .

Farhat M , Cox H , Ghanem M , Denkinger CM , Rodrigues C , Abd El Aziz MS , et al . Drug‑resistant tuberculosis: a persistent global health con‑cern . Nat Rev Microbiol . 2024 ; 22 ( 10 ): 617 – 35 .

Lu Z , Zhang Y , Zhong Y , Qiang L , Ge P , Lei Z , et al . A bacterial effector manipulates host lysosomal protease activity‑dependent plasticity in cell death modalities to facilitate infection . Proc Natl Acad Sci USA . 2025 ; 122 ( 8 ): e2406715122 .

Qiang L , Zhang Y , Lei Z , Lu Z , Tan S , Ge P , et al . A mycobacterial effector promotes ferroptosis‑dependent pathogenicity and dissemination . Nat Commun . 2023 ; 14 ( 1 ): 1430 .

Lombardi A , Villa S , Castelli V , Bandera A , Gori A . T‑cell exhaustion in Mycobacterium tuberculosis and nontuberculous mycobacteria infec‑tion: pathophysiology and therapeutic perspectives . Microorganisms . 2021 ; 9 ( 12 ): 2460 .

Baessler A , Vignali DAA . T cell exhaustion . Annu Rev Immunol . 2024 ; 42 ( 1 ): 179 – 206 .

Jenkins E , Whitehead T , Fellermeyer M , Davis SJ , Sharma S . The current state and future of T‑cell exhaustion research . Oxf Open Immunol . 2023 ; 4 ( 1 ): iqad006 .

Moguche AO , Musvosvi M , Penn‑Nicholson A , Plumlee CR , Mearns H , Geldenhuys H , et al . Antigen availability shapes T cell differentiation and function during tuberculosis . Cell Host Microbe . 2017 ; 21 ( 6 ): 695 – 706 .

Audran R , Karoui O , Donnet L , Soumas V , Fares F , Lovis A , et al . Ran‑domised, double‑blind, controlled phase 1 trial of the candidate tuber‑culosis vaccine ChAdOx1‑85A delivered by aerosol versus intramuscular route . J Infect . 2024 ; 89 ( 2 ): 106205 .

Clemmensen HS , Dube JY , McIntosh F , Rosenkrands I , Jungersen G , Aagaard C , et al . In vivo antigen expression regulates CD4 T cell dif‑ferentiation and vaccine efficacy against Mycobacterium tuberculosis infection . MBio . 2021 ; 12 ( 2 ): 2021.02.02.429488 .

Palma‑Nicolás JP , Hernández‑Pando R , Segura E , Ibarra‑Sánchez MJ , Estrada‑García I , Zentella‑Dehesa A , et al . Mycobacterial di‑O‑acyl tre‑halose inhibits Th‑1 cytokine gene expression in murine cells by down‑modulation of MAPK signaling . Immunobiology . 2010 ; 215 ( 2 ): 143 – 52 .

Ramos‑Espinosa O , Mata‑Espinosa D , Francisco‑Cruz A , López‑Torres MO , Hernández‑Bazán S , Barrios‑Payán J , et al . Immunotherapeutic effect of adenovirus encoding antimicrobial peptides in experimental pulmonary tuberculosis . J Leukoc Biol . 2021 ; 110 ( 5 ): 951 – 63 .

Venkataprasad N , Ledger P , Ivanyi J . The effect of glucosaminylmuramyl dipeptide injection to mice on the course of tuberculous infection and in vitro superoxide anion production . Int Arch Allergy Immunol . 1997 ; 114 ( 1 ): 23 – 9 .

Rivas‑Santiago CE , Rivas‑Santiago B , León DA , Castañeda‑Delgado J , Hernández Pando R . Induction of β‑defensins by l‑isoleucine as novel immunotherapy in experimental murine tuberculosis . Clin Exp Immu‑nol . 2011 ; 164 ( 1 ): 80 – 9 .

Rivas‑Santiago B , Rivas‑Santiago C , Sada E , Hernández‑Pando R . Prophy‑lactic potential of defensins and L‑isoleucine in tuberculosis household contacts: an experimental model . Immunotherapy . 2015 ; 7 ( 3 ): 207 – 13 .

Rivas‑Santiago B , Castañeda‑Delgado JE , Rivas Santiago CE , Waldbrook M , González‑Curiel I , León‑Contreras JC , et al . Ability of innate defence regulator peptides IDR‑1002, IDR‑HH2 and IDR‑1018 to protect against Mycobacterium tuberculosis infections in animal models . PLoS One . 2013 ; 8 ( 3 ): e59119 .

Walter K , Steinwede K , Aly S , Reinheckel T , Bohling J , Maus UA , et al . Cathepsin G in experimental tuberculosis: relevance for antibac‑terial protection and potential for immunotherapy . J Immunol . 2015 ; 195 ( 7 ): 3325 – 33 .

Mir SA , Sharma S . Immunotherapeutic potential of N‑formylated pep‑tides of ESAT‑6 and glutamine synthetase in experimental tuberculosis . Int Immunopharmacol . 2014 ; 18 ( 2 ): 298 – 303 .

Mir SA , Sharma S . Immunotherapeutic potential of an N‑formylated peptide of Listeria monocytogenes in experimental tuberculosis . Immu‑nopharmacol Immunotoxicol . 2019 ; 41 ( 2 ): 292 – 8 .

Mir SA , Sharma S . Adjunctive immunotherapeutic efficacy of N‑formylated internal peptide of mycobacterial glutamine synthetase in mouse model of tuberculosis . Protein Pept Lett . 2020 ; 27 ( 3 ): 236 – 42 .

Mir SA , Verma I , Sharma S . Immunotherapeutic potential of recom‑binant ESAT‑6 protein in mouse model of experimental tuberculosis . Immunol Lett . 2014 ; 158 ( 1–2 ): 88 – 94 .

Pedral‑Sampaio DB , Netto EM , Brites C , Bandeira AC , Guerra C , Barberin MG , et al . Use of Rhu‑GM‑CSF in pulmonary tuberculosis patients: results of a randomized clinical trial . Braz J Infect Dis . 2003 ; 7 ( 4 ): 245 – 52 .

Buccheri S , Reljic R , Caccamo N , Meraviglia S , Ivanyi J , Salerno A , et al . Prevention of the post‑chemotherapy relapse of tuberculous infection by combined immunotherapy . Tuberculosis (Edinb) . 2009 ; 89 ( 1 ): 91 – 4 .

Tran AC , Diogo GR , Paul MJ , Copland A , Hart P , Mehta N , et al . Mucosal therapy of multi‑drug resistant tuberculosis with IgA and interferon‑γ . Front Immunol . 2020 ; 11 : 582833 .

Ivanova LA . Immunotherapy in the combined treatment of chronic destructive pulmonary tuberculosis . Probl Tuberk . 1994 ; 3 : 16 – 9 .

Zhang Y , Liu J , Wang Y , Xian Q , Shao L , Yang Z , et al . Immunotherapy using IL‑2 and GM‑CSF is a potential treatment for multidrug‑resistant Mycobacterium tuberculosis . Sci China Life Sci . 2012 ; 55 ( 9 ): 800 – 6 .

Johnson BJ , Ress SR , Willcox P , Pati BP , Lorgat F , Stead P , et al . Clinical and immune responses of tuberculosis patients treated with low‑dose IL‑2 and multidrug therapy . Cytokines Mol Ther . 1995 ; 1 ( 3 ): 185 – 96 .

Johnson BJ , Bekker LG , Rickman R , Brown S , Lesser M , Ress S , et al . RhuIL‑2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo . Tuber Lung Dis . 1997 ; 78 ( 3–4 ): 195 – 203 .

Johnson BJ , Estrada I , Shen Z , Ress S , Willcox P , Colston MJ , et al . Differ‑ential gene expression in response to adjunctive recombinant human interleukin‑2 immunotherapy in multidrug‑resistant tuberculosis patients . Infect Immun . 1998 ; 66 ( 6 ): 2426 – 33 .

Shen H , Min R , Tan Q , Xie W , Wang H , Pan H , et al . The beneficial effects of adjunctive recombinant human interleukin‑2 for multidrug resistant tuberculosis . Arch Med Sci . 2015 ; 11 ( 3 ): 584 – 90 .

Liu X , Li F , Niu H , Ma L , Chen J , Zhang Y , et al . IL‑2 restores T‑cell dysfunc‑tion induced by persistent Mycobacterium tuberculosis antigen stimula‑tion . Front Immunol . 2019 ; 10 : 2350 .

Johnson B , Bekker LG , Ress S , Kaplan G . Recombinant interleukin 2 adjunctive therapy in multidrug‑resistant tuberculosis . Novartis Found Symp . 1998 ; 217 : 99 – 106 .

Johnson JL , Ssekasanvu E , Okwera A , Mayanja H , Hirsch CS , Nakibali JG , et al . Randomized trial of adjunctive interleukin‑2 in adults with pulmonary tuberculosis . Am J Respir Crit Care Med . 2003 ; 168 ( 2 ): 185 – 91 .

Shouse AN , LaPorte KM , Malek TR . Interleukin‑2 signaling in the regulation of T cell biology in autoimmunity and cancer . Immunity . 2024 ; 57 ( 3 ): 414 – 28 .

Briukhovetska D , Dörr J , Endres S , Libby P , Dinarello CA , Kobold S . Interleukins in cancer: from biology to therapy . Nat Rev Cancer . 2021 ; 21 ( 8 ): 481 – 99 .

Sheng L , Li X , Weng F , Wu S , Chen Y , Lou L . Efficacy and safety of adjunc‑tive recombinant human interleukin‑2 for patients with pulmonary tuberculosis: a meta‑analysis . J Trop Med . 2022 ; 2022 : 5071816 .

Nikolaeva LG , Maystat TV , Pylypchuk VS , Volyanskii YL , Frolov VM , Kutsyna GA . Cytokine profiles of HIV patients with pulmonary tubercu‑losis resulting from adjunct immunotherapy with herbal phytoconcen‑trates Dzherelo and Anemin . Cytokine . 2008 ; 44 ( 3 ): 392 – 6 .

Nikolaeva LG , Maystat TV , Masyuk LA , Pylypchuk VS , Volyanskii YL , Kutsyna GA . Changes in CD4 + T‑cells and HIV RNA resulting from combination of anti‑TB therapy with Dzherelo in TB/HIV dually infected patients . Drug Des Devel Ther . 2009 ; 2 : 87 – 93 .

Qiao M , Li S , Yuan J , Ren W , Shang Y , Wang W , et al . Delamanid sup‑presses CXCL10 expression via regulation of JAK/STAT1 signaling and correlates with reduced inflammation in tuberculosis patients . Front Immunol . 2022 ; 13 : 923492 .

Batbold U , Butov DO , Kutsyna GA , Damdinpurev N , Grinishina EA , Mijid‑dorj O , et al . Double‑blind, placebo‑controlled, 1: 1 randomized phase III clinical trial of immunoxel honey lozenges as an adjunct immuno‑therapy in 269 patients with pulmonary tuberculosis . Immunotherapy . 2017 ; 9 ( 1 ): 13 – 24 .

Shamkuwar CA , Meshram SH , Mahakalkar SM . Levamisole as an adjuvant to short‑course therapy in newly diagnosed pulmonary tuber‑culosis patients . Adv Biomed Res . 2017 ; 6 : 37 .

Butov D , Zaitseva S , Butova T , Stepanenko G , Pogorelova O , Zheleznia‑kova N . Efficacy and safety of quercetin and polyvinylpyrrolidone in treatment of patients with newly diagnosed destructive pulmonary tuberculosis in comparison with standard antimycobacterial therapy . Int J Mycobacteriol . 2016 ; 5 ( 4 ): 446 – 53 .

Bekele A , Gebreselassie N , Ashenafi S , Kassa E , Aseffa G , Amogne W , et al . Daily adjunctive therapy with vitamin D 3 and phenylbutyrate supports clinical recovery from pulmonary tuberculosis: a randomized controlled trial in Ethiopia . J Intern Med . 2018 ; 284 ( 3 ): 292 – 306 .

Dlugovitzky D , Notario R , Martinel‑Lamas D , Fiorenza G , Farroni M , Bogue C , et al . Immunotherapy with oral, heat‑killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis . Immunotherapy . 2010 ; 2 ( 2 ): 159 – 69 .

Corlan E , Marica C , Macavei C , Stanford JL , Stanford CA . Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania.1. Newly‑diagnosed pulmonary disease . Respir Med . 1997 ; 91 ( 1 ): 13 – 9 .

Dlugovitzky D , Fiorenza G , Farroni M , Bogue C , Stanford C , Stanford J . Immunological consequences of three doses of heat‑killed Mycobacterium vaccae in the immunotherapy of tuberculosis . Respir Med . 2006 ; 100 ( 6 ): 1079 – 87 .

Mwinga A , Nunn A , Ngwira B , Chintu C , Warndorff D , Fine P , et al . Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV‑infected adults with pulmonary tuberculosis: a randomised placebo‑controlled trial . Lancet . 2002 ; 360 ( 9339 ): 1050 – 5 .

Luo Y . National Cooperation Group on Clinical Study of Mycobacterium vaccae Vaccine. The immunotherapeutic effect of Mycobacterium vac‑cae vaccine on initially treated pulmonary tuberculosis . Zhonghua Jie He He Hu Xi Za Zhi . 2001 ; 24 ( 1 ): 43 – 7 .

Wang W , Jin G , Ye Y , Xia X , Wang A , Zhuang Y , et al . A clinical study on vaccine of Mycobacterium vaccae in treating pulmonary tuberculosis . Zhonghua Jie He He Hu Xi Za Zhi . 1999 ; 22 ( 2 ): 108 – 10 .

Stanford JL , Stanford CA , Grange JM , Lan NN , Etemadi A . Does immu‑notherapy with heat‑killed Mycobacterium vaccae offer hope for the treatment of multi‑drug‑resistant pulmonary tuberculosis? Respir Med . 2001 ; 95 ( 6 ): 444 – 7 .

Johnson JL , Kamya RM , Okwera A , Loughlin AM , Nyole S , Hom DL , et al . Randomized controlled trial of Mycobacterium vaccae immuno‑therapy in non‑human immunodeficiency virus‑infected Ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda‑Case Western Reserve University research collaboration . J Infect Dis . 2000 ; 181 ( 4 ): 1304 – 12 .

Bahr GM , Shaaban MA , Gabriel M , al‑Shimali B , Siddiqui Z , Chugh TD , et al . Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae . Tubercle . 1990 ; 71 ( 4 ): 259 – 66 .

Corlan E , Marica C , Macavei C , Stanford JL , Stanford CA . Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Roma‑nia. 2. Chronic or relapsed disease . Respir Med . 1997 ; 91 ( 1 ): 21 – 9 .

Corrah T , Byass P , Jaffar S , Thomas V , Bouchier V , Stanford JL , et al . Prior BCG vaccination improves survival of Gambian patients treated for pulmonary tuberculosis . Trop Med Int Health . 2000 ; 5 ( 6 ): 413 – 7 .

Mayosi BM , Ntsekhe M , Bosch J , Pandie S , Jung H , Gumedze F , et al . Prednisolone and Mycobacterium indicus pranii in tuberculous pericardi‑tis . N Engl J Med . 2014 ; 371 ( 12 ): 1121 – 30 .

Sharma SK , Katoch K , Sarin R , Balambal R , Kumar Jain N , Patel N , et al . Efficacy and safety of Mycobacterium indicus pranii as an adjunct therapy in category II pulmonary tuberculosis in a randomized trial . Sci Rep . 2017 ; 7 ( 1 ): 3354 .

Bourinbaiar AS , Batbold U , Efremenko Y , Sanjagdorj M , Butov D , Damdinpurev N , et al . Phase III, placebo‑controlled, randomized, double‑blind trial of tableted, therapeutic TB vaccine (V7) containing heat‑killed M. vaccae administered daily for one month . J Clin Tuberc Other Mycobact Dis . 2020 ; 18 : 100141 .

Butov DA , Efremenko YV , Prihoda ND , Zaitzeva SI , Yurchenko LV , Sokolenko NI , et al . Randomized, placebo‑controlled phase II trial of heat‑killed Mycobacterium vaccae (immodulon batch) formulated as an oral pill (V7) . Immunotherapy . 2013 ; 5 ( 10 ): 1047 – 54 .

Butov DA , Pashkov YN , Stepanenko AL , Choporova AI , Butova TS , Batdelger D , et al . Phase IIb randomized trial of adjunct immunotherapy in patients with first‑diagnosed tuberculosis, relapsed and multi‑drug‑resistant (MDR) TB . J Immune Based Ther Vaccines . 2011 ; 9 : 3 .

Lei JP , Xiong GL , Hu QF , Li Y , Zong PL , Tu SH , et al . Immunotherapeutic efficacy of BCG vaccine in pulmonary tuberculosis and its preventive effect on multidrug‑resistant tuberculosis . Zhonghua Yu Fang Yi Xue Za Zhi . 2008 ; 42 ( 2 ): 86 – 9 .

Nell AS , D’Lom E , Bouic P , Sabaté M , Bosser R , Picas J , et al . Safety, toler‑ability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo‑controlled phase II clinical trial in patients with latent tuberculosis infection . PLoS One . 2014 ; 9 ( 2 ): e89612 .

Van Der Meeren O , Hatherill M , Nduba V , Wilkinson RJ , Muyoyeta M , Van Brakel E , et al . Phase 2b controlled trial of M72/AS01 E vaccine to prevent tuberculosis . N Engl J Med . 2018 ; 379 ( 17 ): 1621 – 34 .

Jenum S , Tonby K , Rueegg CS , Rühwald M , Kristiansen MP , Bang P , et al . A phase I/II randomized trial of H56: IC31 vaccination and adjunctive cyclooxygenase‑2‑inhibitor treatment in tuberculosis patients . Nat Commun . 2021 ; 12 ( 1 ): 6774 .

Liang J , Fu L , Li M , Chen Y , Wang Y , Lin Y , et al . Allogeneic Vγ9Vδ2 T‑cell therapy promotes pulmonary lesion repair: an open‑label, single‑arm pilot study in patients with multidrug‑resistant tuberculosis . Front Immunol . 2021 ; 12 : 756495 .

Erokhin VV , Vasil’eva IA , Konopliannikov AG , Chukanov VI , Tsyb AF , Bagdasarian TR , et al . Systemic transplantation of autologous mesen‑chymal stem cells of the bone marrow in the treatment of patients with multidrug‑resistant pulmonary tuberculosis . Probl Tuberk Bolezn Legk . 2008 ; 10 : 3 – 6 .

Skrahin A , Ahmed RK , Ferrara G , Rane L , Poiret T , Isaikina Y , et al . Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug‑resistant tuberculosis: an open‑label phase 1 safety trial . Lancet Respir Med . 2014 ; 2 ( 2 ): 108 – 22 .

Tang P , Chen X , Xu J , Hu Y , Ye Z , Wang X , et al . Autologous cytokine‑induced killer cell immunotherapy enhances chemotherapy efficacy against multidrug‑resistant tuberculosis . J Immunol Res . 2022 ; 2022 : 2943113 .

Smith S , Lopez S , Kim A , Kasteri J , Olumuyide E , Punu K , et al . Interleukin 24: signal transduction pathways . Cancers (Basel) . 2023 . https://doi.org/10.3390/cancers15133365 .

Zhong Y , Zhang X , Chong W . Interleukin‑24 immunobiology and its roles in inflammatory diseases . Int J Mol Sci . 2022 . https://doi.org/10.3390/ijms23020627 .

Jin SH , Choi D , Chun YJ , Noh M . Keratinocyte‑derived IL‑24 plays a role in the positive feedback regulation of epidermal inflammation in response to environmental and endogenous toxic stressors . Toxicol Appl Pharmacol . 2014 ; 280 ( 2 ): 199 – 206 .

Raguraman R , Munshi A , Ramesh R . Interleukin‑24: a multidimen‑sional therapeutic for treatment of human diseases . Wiley Interdiscip Rev Nanomed Nanobiotechnol . 2025 ; 17 ( 3 ): e70013 .

Ma Y , Chen HD , Wang Y , Wang Q , Li Y , Zhao Y , et al . Interleukin 24 as a novel potential cytokine immunotherapy for the treat‑ment of Mycobacterium tuberculosis infection . Microbes Infect . 2011 ; 13 ( 12–13 ): 1099 – 110 .

Aravind A , Shaji V , Ahmed M , Dagamajalu S , Vijayakumar M , Prasad TSK , et al . An assembled molecular signaling map of interleukin‑24: a resource to decipher its multifunctional immunoregulatory role in pathophysiological conditions . Front Immunol . 2025 ; 16 : 1608101 .

Muromoto R , Oritani K , Matsuda T . Current understanding of the role of tyrosine kinase 2 signaling in immune responses . World J Biol Chem . 2022 ; 13 ( 1 ): 1 – 14 .

Chen H , Ge X , Li C , Zeng J , Wang X . Structure and assembly of the human IL‑12 signaling complex . Structure . 2024 ; 32 ( 10 ): 1640 – 51 .

Hu X , Li J , Fu M , Zhao X , Wang W . The JAK/STAT signaling pathway: from bench to clinic . Signal Transduct Target Ther . 2021 ; 6 ( 1 ): 402 .

Glassman CR , Mathiharan YK , Jude KM , Su L , Panova O , Lupar‑dus PJ , et al . Structural basis for IL‑12 and IL‑23 receptor sharing reveals a gateway for shaping actions on T versus NK cells . Cell . 2021 ; 184 ( 4 ): 983 – 99 .

Nolt D , Flynn JL . Interleukin‑12 therapy reduces the number of immune cells and pathology in lungs of mice infected with Mycobacterium tuberculosis . Infect Immun . 2004 ; 72 ( 5 ): 2976 – 88 .

Liu Y , Pan R , Ouyang Y , Gu W , Xiao T , Yang H , et al . Pyroptosis in health and disease: mechanisms, regulation and clinical perspective . Signal Transduct Target Ther . 2024 ; 9 ( 1 ): 245 .

Wang X , Yang C , Quan C , Li J , Hu Y , Liu P , et al . The regulation and potential role of interleukin‑32 in tuberculous pleural effusion . Front Immunol . 2024 ; 15 : 1342641 .

Zhu L , Cao W , Li B , Yang R , Wang Y , Wu H , et al . IL‑32 positively regulates the AEBP1‑IκBα‑NF‑κB‑TNF‑α axis to inhibit Mycobacterium tuberculosis infection in human macrophages . Microb Pathog . 2025 ; 208 : 107944 .

Maeurer MJ , Trinder P , Hommel G , Walter W , Freitag K , Atkins D , et al . Interleukin‑7 or interleukin‑15 enhances survival of Mycobacterium tuberculosis ‑infected mice . Infect Immun . 2000 ; 68 ( 5 ): 2962 – 70 .

Park J , Kim H , Kwon KW , Choi HH , Kang SM , Hong JJ , et al . Toll‑like receptor 4 signaling‑mediated responses are critically engaged in opti‑mal host protection against highly virulent Mycobacterium tuberculosis K infection . Virulence . 2020 ; 11 ( 1 ): 430 – 45 .

Redford PS , Boonstra A , Read S , Pitt J , Graham C , Stavropoulos E , et al . Enhanced protection to Mycobacterium tuberculosis infection in IL‑10‑deficient mice is accompanied by early and enhanced Th1 responses in the lung . Eur J Immunol . 2010 ; 40 ( 8 ): 2200 – 10 .

Buccheri S , Reljic R , Caccamo N , Ivanyi J , Singh M , Salerno A , et al . IL‑4 depletion enhances host resistance and passive IgA protec‑tion against tuberculosis infection in BALB/c mice . Eur J Immunol . 2007 ; 37 ( 3 ): 729 – 37 .

Patel NR , Swan K , Li X , Tachado SD , Koziel H . Impaired M. tuberculosis ‑mediated apoptosis in alveolar macrophages from HIV + persons: potential role of IL‑10 and BCL‑3 . J Leukoc Biol . 2009 ; 86 ( 1 ): 53 – 60 .

Richardson ET , Shukla S , Sweet DR , Wearsch PA , Tsichlis PN , Boom WH , et al . Toll‑like receptor 2‑dependent extracellular signal‑regulated kinase signaling in Mycobacterium tuberculosis ‑infected macrophages drives anti‑infl ammatory responses and inhibits Th1 polarization of responding T cells . Infect Immun . 2015 ; 83 ( 6 ): 2242 – 54 .

O’Leary S , O’Sullivan MP , Keane J . IL‑10 blocks phagosome maturation in Mycobacterium tuberculosis ‑infected human macrophages . Am J Respir Cell Mol Biol . 2011 ; 45 ( 1 ): 172 – 80 .

Park HS , Back YW , Jang IT , Lee KI , Son YJ , Choi HG , et al . Mycobacterium tuberculosis Rv2145c promotes intracellular survival by STAT3 and IL‑10 receptor signaling . Front Immunol . 2021 ; 12 : 666293 .

Huang Y , Li R , Chen S , Wang Q , Han Z , Liang Y , et al . Monocar‑boxylate transporter 4 facilitates Mycobacterium tuberculosis survival through NF‑κB p65‑mediated interleukin‑10 production . iScience . 2024 ; 27 ( 8 ): 110238 .

Khan A , Zhang K , Singh VK , Mishra A , Kachroo P , Bing T , et al . Human M1 macrophages express unique innate immune response genes after mycobacterial infection to defend against tuberculosis . Commun Biol . 2022 ; 5 ( 1 ): 480 .

Li Y , Cong Y , Jia M , He Q , Zhong H , Zhao Y , et al . Targeting IL‑21 to tumor‑reactive T cells enhances memory T cell responses and anti‑PD‑1 antibody therapy . Nat Commun . 2021 ; 12 ( 1 ): 951 .

Macias AE , Guaní‑Guerra E . Transfer factor: myths and facts . Arch Med Res . 2020 ; 51 ( 7 ): 613 – 22 .

Habar TR , Islam AA , Hatta M , Warsinggih , Mahmudi A , Massi MN , et al . Transfer factor treatment in management of peritonitis condition: an experimental study in rat . Ann Med Surg (Lond) . 2021 ; 69 : 102755 .

Fabre RA , Pérez TM , Aguilar LD , Rangel MJ , Estrada‑Garcìa I , Hernández‑Pando R , et al . Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis . Clin Exp Immunol . 2004 ; 136 ( 2 ): 215 – 23 .

Rubinstein A , Melamed J , Rodescu D , Murphy RA , Broocker D . Transfer factor treatment in a patient with progressive tuberculosis . Clin Immu‑nol Immunopathol . 1977 ; 8 ( 1 ): 39 – 50 .

Ebrahimi SB , Samanta D . Engineering protein‑based therapeutics through structural and chemical design . Nat Commun . 2023 ; 14 ( 1 ): 2411 .

Binder U , Skerra A . Strategies for extending the half‑life of bio‑therapeutics: successes and complications . Expert Opin Biol Ther . 2025 ; 25 ( 1 ): 93 – 118 .

Cini JK , Kenney RT , Dexter S , McAndrew SJ , Eraslan RN , Brody R , et al . Son‑1010: an albumin‑binding IL‑12 fusion protein that improves cytokine half‑life, targets tumors, and enhances therapeutic efficacy . Front Immunol . 2024 ; 15 : 1493257 .

Hamilton JA . GM‑CSF in inflammation . J Exp Med . 2020 ; 217 ( 1 ): e20190945 .

Lazarus HM , Pitts K , Wang T , Lee E , Buchbinder E , Dougan M , et al . Recombinant GM‑CSF for diseases of GM‑CSF insufficiency: correct‑ing dysfunctional mononuclear phagocyte disorders . Front Immunol . 2022 ; 13 : 1069444 .

David C , Verney C , Si‑Tahar M , Guillon A . Evaluating the evidence for GM‑CSF as a host‑directed therapy in respiratory infections . Cytokine . 2025 ; 189 : 156902 .

Bryson BD , Rosebrock TR , Tafesse FG , Itoh CY , Nibasumba A , Babu‑novic GH , et al . Heterogeneous GM‑CSF signaling in macrophages is associated with control of Mycobacterium tuberculosis . Nat Commun . 2019 ; 10 ( 1 ): 2329 .

Mishra A , Singh VK , Jagannath C , Subbian S , Restrepo BI , Gauduin MC , et al . Human macrophages exhibit GM‑CSF dependent restriction of Mycobacterium tuberculosis infection via regulating their self‑survival, differentiation and metabolism . Front Immunol . 2022 ; 13 : 859116 .

Chuang YM , He L , Pinn ML , Tsai YC , Cheng MA , Farmer E , et al . Albumin fusion with granulocyte‑macrophage colony‑stimulating factor acts as an immunotherapy against chronic tuberculosis . Cell Mol Immunol . 2021 ; 18 ( 10 ): 2393 – 401 .

Carvalho NB , de Lourdes BM , Souza AS , Netto EM , Arruda S , Santos SB , et al . Impaired TNF, IL‑1β, and IL‑17 production and increased susceptibility to Mycobacterium tuberculosis infection in HTLV‑1 infected individuals . Tuberculosis (Edinb) . 2018 ; 108 : 35 – 40 .

Back YW , Shin KW , Choi S , Park HS , Lee KI , Choi HG , et al . Mycobacterium tuberculosis Rv2005c induces dendritic cell maturation and Th1 responses and exhibits immunotherapeutic activity by fusion with the Rv2882c protein . Vaccines . 2020 ; 8 ( 3 ): 370 .

Parveen S , Lun S , Urbanowski ME , Cardin M , Shen J , Murphy JR , et al . Effective host‑directed therapy for tuberculosis by depletion of myeloid‑derived suppressor cells and related cells using a diphtheria toxin fusion protein . J Infect Dis . 2021 ; 224 ( 11 ): 1962 – 72 .

Hermann C , King CG . Tb or not to be: what specificities and impact do antibodies have during tuberculosis? Oxf Open Immunol . 2021 ; 2 ( 1 ): iqab015 .

Davies LRL , Wang C , Steigler P , Bowman KA , Fischinger S , Hatherill M , et al . Age and sex influence antibody profiles associated with tubercu‑losis progression . Nat Microbiol . 2024 ; 9 ( 6 ): 1513 – 25 .

Irvine EB , Darrah PA , Wang S , Wang C , McNamara RP , Roederer M , et al . Humoral correlates of protection against Mycobacterium tuberculosis following intravenous BCG vaccination in rhesus macaques . iScience . 2024 ; 27 ( 12 ): 111128 .

Olivares N , Marquina B , Mata‑Espinoza D , Zatarain‑Barron ZL , Pinzón CE , Estrada I , et al . The protective effect of immunoglobulin in murine tuberculosis is dependent on IgG glycosylation . Pathog Dis . 2013 ; 69 ( 3 ): 176 – 83 .

Grace PS , Peters JM , Sixsmith J , Lu R , Irvine EB , Luedeman C , et al . Antibody‑Fab and ‑Fc features promote Mycobacterium tuberculosis restriction . Immunity . 2025 ; 58 ( 6 ): 1586 – 97 .

Krishnananthasivam S , Li H , Bouzeyen R , Shunmuganathan B , Purusho‑torman K , Liao X , et al . An anti‑LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis . NPJ Vaccines . 2023 ; 8 ( 1 ): 127 .

Corrigan DT , Ishida E , Chatterjee D , Lowary TL , Achkar JM . Monoclonal antibodies to lipoarabinomannan/arabinomannan—characteristics and implications for tuberculosis research and diagnostics . Trends Microbiol . 2023 ; 31 ( 1 ): 22 – 35 .

Teitelbaum R , Glatman‑Freedman A , Chen B , Robbins JB , Unanue E , Casadevall A , et al . A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival . Proc Natl Acad Sci U S A . 1998 ; 95 ( 26 ): 15688 – 93 .

Pethe K , Alonso S , Biet F , Delogu G , Brennan MJ , Locht C , et al . The heparin‑binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination . Nature . 2001 ; 412 ( 6843 ): 190 – 4 .

Hamasur B , Haile M , Pawlowski A , Schroder U , Kallenius G , Svenson SB . A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab′) fragment prolong survival of mice infected with Mycobacterium tuberculosis . Clin Exp Immunol . 2004 ; 138 ( 1 ): 30 – 8 .

Williams A , Reljic R , Naylor I , Clark SO , Falero‑Diaz G , Singh M , et al . Pas‑sive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs . Immunology . 2004 ; 111 ( 3 ): 328 – 33 .

López Y , Yero D , Falero‑Diaz G , Olivares N , Sarmiento ME , Sifontes S , et al . Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16kDa protein in a model of pro‑gressive pulmonary infection . Int J Med Microbiol . 2009 ; 299 ( 6 ): 447 – 52 .

Balu S , Reljic R , Lewis MJ , Pleass RJ , McIntosh R , van Kooten C , et al . A novel human IgA monoclonal antibody protects against tuberculosis . J Immunol . 2011 ; 186 ( 5 ): 3113 – 9 .

Hernández‑Pando R , Orozco‑Esteves H , Maldonado HA , Aguilar‑León D , Vilchis‑Landeros MM , Mata‑Espinosa DA , et al . A combination of a trans‑forming growth factor‑beta antagonist and an inhibitor of cyclooxyge‑nase is an effective treatment for murine pulmonary tuberculosis . Clin Exp Immunol . 2006 ; 144 ( 2 ): 264 – 72 .

Giri PK , Verma I , Khuller GK . Adjunct immunotherapy with Ag85 com‑plex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection . Immunotherapy . 2009 ; 1 ( 1 ): 31 – 7 .

Dwivedi VP , Bhattacharya D , Singh M , Bhaskar A , Kumar S , Fatima S , et al . Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection . J Ethnopharmacol . 2019 ; 243 : 111634 .

Mourik BC , Leenen PJ , de Knegt GJ , Huizinga R , van der Eerden BC , Wang J , et al . Immunotherapy added to antibiotic treatment reduces relapse of disease in a mouse model of tuberculosis . Am J Respir Cell Mol Biol . 2017 ; 56 ( 2 ): 233 – 41 .

Lim J , Koh VHQ , Cho SSL , Periaswamy B , Choi DPS , Vacca M , et al . Harnessing the immunomodulatory properties of bacterial ghosts to boost the anti‑mycobacterial protective immunity . Front Immunol . 2019 ; 10 : 2737 .

Kumar S , Sharma C , Kaushik SR , Kulshreshtha A , Chaturvedi S , Nanda RK , et al . The phytochemical bergenin as an adjunct immunotherapy for tuberculosis in mice . J Biol Chem . 2019 ; 294 ( 21 ): 8555 – 63 .

Gupta S , Cheung L , Pokkali S , Winglee K , Guo H , Murphy JR , et al . Suppressor cell‑depleting immunotherapy with denileukin diftitox is an effective host‑directed therapy for tuberculosis . J Infect Dis . 2017 ; 215 ( 12 ): 1883 – 7 .

Gupta N , Vedi S , Garg S , Loo E , Li J , Kunimoto DY , et al . Harnessing innate immunity to treat Mycobacterium tuberculosis infections: heat‑killed Caulobacter crescentus as a novel biotherapeutic . Cells . 2023 ; 12 ( 4 ): 560 .

Singh DK , Tousif S , Bhaskar A , Devi A , Negi K , Moitra B , et al . Luteolin as a potential host‑directed immunotherapy adjunct to isoniazid treatment of tuberculosis . PLoS Pathog . 2021 ; 17 ( 8 ): e1009805 .

Liang Y , Gong W , Wang X , Zhang J , Ling Y , Song J , et al . Chinese tradi‑tional medicine NiuBeiXiaoHe (NBXH) extracts have the function of antituberculosis and immune recovery in BALB/c mice . J Immunol Res . 2021 ; 2021 : 6234560 .

Sali M , Delogu G , Greco E , Rocca S , Colizzi V , Fadda G , et al . Exploit‑ing immunotherapy in Mycobacterium tuberculosis ‑infected mice: sphingosine 1‑phosphate treatment results in a protective or det‑rimental effect depending on the stage of infection . Int J Immuno‑pathol Pharmacol . 2009 ; 22 ( 1 ): 175 – 81 .

Bhattacharya D , Dwivedi VP , Kumar S , Reddy MC , Van Kaer L , Moodley P , et al . Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis . J Biol Chem . 2014 ; 289 ( 48 ): 33404 – 11 .

Kumari A , Pahuja I , Negi K , Ghoshal A , Mukopadhyay S , Agarwal M , et al . Withaferin a protects against primary and recurrent tuberculosis by modulating mycobacterium‑specific host immune responses . Microbiol Spectr . 2023 ; 11 ( 2 ): e0058323 .

Shen H , Yang E , Guo M , Yang R , Huang G , Peng Y , et al . Adjunc‑tive zoledronate + IL‑2 administrations enhance anti‑tuberculosis Vγ2Vδ2 T‑effector populations, and improve treatment outcome of multidrug‑resistant tuberculosis 1 . Emerg Microbes Infect . 2022 ; 11 ( 1 ): 1790 – 805 .

Bhaskar A , Kumari A , Singh M , Kumar S , Kumar S , Dabla A , et al . [6]‑gin‑gerol exhibits potent anti‑mycobacterial and immunomodulatory activity against tuberculosis . Int Immunopharmacol . 2020 ; 87 : 106809 .

Duan LY , Liang Y , Gong WP , Xue Y , Mi J , Wang J , et al . Comparative study on the antituberculous effect and mechanism of the traditional Chinese medicines NiuBeiXiaoHe extract and JieHeWan . Mil Med Res . 2021 ; 8 ( 1 ): 34 .

Chen JQ , Szodoray P , Zeher M . Toll‑like receptor pathways in autoim‑mune diseases . Clin Rev Allergy Immunol . 2016 ; 50 ( 1 ): 1 – 17 .

McGuire VA , Arthur JS . Subverting toll‑like receptor signaling by bacte‑rial pathogens . Front Immunol . 2015 ; 6 : 607 .

Ciaston I , Dobosz E , Potempa J , Koziel J . The subversion of Toll‑like receptor signaling by bacterial and viral proteases during the develop‑ment of infectious diseases . Mol Aspects Med . 2022 ; 88 : 101143 .

Francisco S , Billod JM , Merino J , Punzón C , Gallego A , Arranz A , et al . Induction of TLR4/TLR2 interaction and heterodimer formation by low endotoxic atypical LPS . Front Immunol . 2021 ; 12 : 748303 .

Owen AM , Luan L , Burelbach KR , McBride MA , Stothers CL , Boykin OA , et al . MyD88‑dependent signaling drives toll‑like receptor‑induced trained immunity in macrophages . Front Immunol . 2022 ; 13 : 1044662 .

Niu W , Sun B , Li M , Cui J , Huang J , Zhang L . TLR‑4/microRNA‑125a/NF‑κB signaling modulates the immune response to Mycobacterium tuberculosis infection . Cell Cycle . 2018 ; 17 ( 15 ): 1931 – 45 .

Zhang ZM , Zhang AR , Xu M , Lou J , Qiu WQ . TLR‑4/miRNA‑32‑5p/FSTL1 signaling regulates mycobacterial survival and inflammatory responses in Mycobacterium tuberculosis ‑infected macrophages . Exp Cell Res . 2017 ; 352 ( 2 ): 313 – 21 .

Khan N , Pahari S , Vidyarthi A , Aqdas M , Agrewala JN . Stimulation through CD40 and TLR‑4 is an effective host directed therapy against Mycobacterium tuberculosis . Front Immunol . 2016 ; 7 : 386 .

Pahari S , Negi S , Aqdas M , Arnett E , Schlesinger LS , Agrewala JN . Induction of autophagy through CLEC4E in combination with TLR4: an innovative strategy to restrict the survival of Mycobacterium tuberculosis . Autophagy . 2020 ; 16 ( 6 ): 1021 – 43 .

Khan N , Pahari S , Vidyarthi A , Aqdas M , Agrewala JN . NOD‑2 and TLR‑4 signaling reinforces the efficacy of dendritic cells and reduces the dose of TB drugs against Mycobacterium tuberculosis . J Innate Immun . 2016 ; 8 ( 3 ): 228 – 42 .

Weng S , Zhang J , Ma H , Zhou J , Jia L , Wan Y , et al . B21 DNA vaccine expressing ag85b, rv2029c, and rv1738 confers a robust therapeutic effect against latent Mycobacterium tuberculosis infection . Front Immu‑nol . 2022 ; 13 : 1025931 .

Fávaro WJ , Nunes OS , Seiva FR , Nunes IS , Woolhiser LK , Durán N , et al . Effects of P‑MAPA immunomodulator on Toll‑like receptors and p53: potential therapeutic strategies for infectious diseases and cancer . Infect Agent Cancer . 2012 ; 7 ( 1 ): 14 .

Gonçalves MT , Squaiella‑Baptistão CC , Pidde G , Lopes PH , da Silva Nunes I , Tambourgi DV . P‑MAPA a fungi‑derived immunomodulatory compound, induces a proinflammatory response in a human whole blood model . Mediators Inflamm . 2020 ; 2020 : 8831389 .

Larsen SE , Rais M , Reese VA , Ferede D , Pecor T , Kaur S , et al . Characteriz‑ing TLR4 agonist EmT4 TM as an anti‑ Mycobacterium tuberculosis vaccine adjuvant . Immunohorizons . 2025 . https://doi.org/10.1093/immhor/vlaf014 .

Gopalakrishnan A , Salgame P . Toll‑like receptor 2 in host defense against Mycobacterium tuberculosis : to be or not to be‑that is the ques‑tion . Curr Opin Immunol . 2016 ; 42 : 76 – 82 .

Hu W , Spaink HP . The role of TLR2 in infectious diseases caused by mycobacteria: from cell biology to therapeutic target . Biol . 2022 . https://doi.org/10.3390/biology11020246 .

Chodisetti SB , Gowthaman U , Rai PK , Vidyarthi A , Khan N , Agrewala JN . Triggering through toll‑like receptor 2 limits chronically stimu‑lated T‑helper type 1 cells from undergoing exhaustion . J Infect Dis . 2015 ; 211 ( 3 ): 486 – 96 .

Gowthaman U , Singh V , Zeng W , Jain S , Siddiqui KF , Chodisetti SB , et al . Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against Mycobacterium tuberculosis by evoking enduring memory T‑cell response . J Infect Dis . 2011 ; 204 ( 9 ): 1328 – 38 .

López M , Sly LM , Luu Y , Young D , Cooper H , Reiner NE . The 19‑kD Mycobacterium tuberculosis protein induces macrophage apoptosis through Toll‑like receptor‑2 . J Immunol . 2003 ; 170 ( 5 ): 2409 – 16 .

Shin DM , Yuk JM , Lee HM , Lee SH , Son JW , Harding CV , et al . Mycobacte‑rial lipoprotein activates autophagy via TLR2/1/CD14 and a functional vitamin D receptor signalling . Cell Microbiol . 2010 ; 12 ( 11 ): 1648 – 65 .

Kitenge M , Phiri B , Pheeha SM , Ogunrombi M , Nyasulu PS . Dzherelo (immunoxel) as adjunctive therapy to standard antituberculosis treat‑ment in patients with pulmonary tuberculosis: a systematic review and meta‑analysis of clinical trials . Syst Rev . 2021 ; 10 ( 1 ): 157 .

Ma T , Xia T . Nanoparticle‑based activatable probes for bioimaging . Adv Biol . 2021 ; 5 ( 1 ): e2000193 .

Simberg D , Barenholz Y , Roffler SR , Landfester K , Kabanov AV , Moghimi SM . Pegylation technology: addressing concerns, moving forward . Drug Deliv . 2025 ; 32 ( 1 ): 2494775 .

Lammers T . Nanomedicine tumor targeting . Adv Mater . 2024 ; 36 ( 26 ): e2312169 .

Li X , Hu Y , Zhang X , Shi X , Parak WJ , Pich A . Transvascular transport of nanocarriers for tumor delivery . Nat Commun . 2024 ; 15 ( 1 ): 8172 .

Wang B , Hu S , Teng Y , Chen J , Wang H , Xu Y , et al . Current advance of nanotechnology in diagnosis and treatment for malignant tumors . Signal Transduct Target Ther . 2024 ; 9 ( 1 ): 200 .

Coleman MM , Basdeo SA , Coleman AM , Cheallaigh CN , Peral de Castro C , McLaughlin AM , et al . All‑trans retinoic acid augments autophagy during intracellular bacterial infection . Am J Respir Cell Mol Biol . 2018 ; 59 ( 5 ): 548 – 56 .

Aintablian A , Arold AM , Alattar H , Cyran L , Schoen C , Du Plessis N , et al . MDSC depletion during immunization with heat‑killed Mycobacterium tuberculosis increases protection against BCG infection . Front Immunol . 2025 ; 16 : 1646526 .

Bahlool AZ , Cavanagh B , Sullivan AO , MacLoughlin R , Keane J , Sullivan MPO , et al . Microfluidics produced ATRA‑loaded PLGA NPs reduced tuberculosis burden in alveolar epithelial cells and enabled high delivered dose under simulated human breathing pattern in 3D printed head models . Eur J Pharm Sci . 2024 ; 196 : 106734 .

Zarei H , Movahedin M , Ganji F , Ghiaseddin A . Retinoic acid‑releasing scaffold based on chitosan hydrogel and testis decellular plates . Bioim‑pacts . 2025 ; 15 : 30007 .

Bahlool AZ , Fattah S , O’Sullivan A , Cavanagh B , MacLoughlin R , Keane J , et al . Development of inhalable ARTA‑loaded PLGA nanoparticles as host‑directed immunotherapy against tuberculosis . Pharmaceutics . 2022 ; 14 ( 8 ): 1745 .

Tian N , Duan H , Cao T , Dai G , Sheng G , Chu H , et al . Macrophage‑targeted nanoparticles mediate synergistic photodynamic therapy and immunotherapy of tuberculosis . RSC Adv . 2023 ; 13 ( 3 ): 1727 – 37 .

Zhang H , Cheng T , Lai L , Deng S , Yu R , Qiu L , et al . BN nanospheres functionalized with mesoporous silica for enhancing CPG oligo‑deoxynucleotide‑mediated cancer immunotherapy . Nanoscale . 2018 ; 10 ( 30 ): 14516 – 24 .

Silva JP , Gonçalves C , Costa C , Sousa J , Silva‑Gomes R , Castro AG , et al . Delivery of LLKKK18 loaded into self‑assembling hyaluronic acid nano‑gel for tuberculosis treatment . J Control Release . 2016 ; 235 : 112 – 24 .

Santos JC , Silva‑Gomes S , Silva JP , Gama M , Rosa G , Gallo RL , et al . Endogenous cathelicidin production limits inflammation and protec‑tive immunity to Mycobacterium avium in mice . Immunity Inflamm Dis . 2014 ; 2 ( 1 ): 1 – 12 .

D’Souza S , Du Plessis SM , Egieyeh S , Bekale RB , Maphasa RE , Irabin AF , et al . Physicochemical and biological evaluation of curdlan‑poly (lactic‑co‑glycolic acid) nanoparticles as a host‑directed therapy against Mycobacterium tuberculosis . J Pharm Sci . 2022 ; 111 ( 2 ): 469 – 78 .

Nuhn L , Vanparijs N , De Beuckelaer A , Lybaert L , Verstraete G , Deswarte K , et al . Ph‑degradable imidazoquinoline‑ligated nanogels for lymph node‑focused immune activation . Proc Natl Acad Sci USA . 2016 ; 113 ( 29 ): 8098 – 103 .

Tousif S , Singh DK , Mukherjee S , Ahmad S , Arya R , Nanda R , et al . Nanoparticle‑formulated curcumin prevents post‑therapeutic disease reactivation and reinfection with Mycobacterium tuberculosis following isoniazid therapy . Front Immunol . 2017 ; 8 : 739 .

Charoenngam N , Holick MF . Immunologic effects of vitamin D on human health and disease . Nutrients . 2020 ; 12 ( 7 ): 2907 .

Ghaseminejad‑Raeini A , Ghaderi A , Sharafi A , Nematollahi‑Sani B , Moos‑savi M , Derakhshani A , et al . Immunomodulatory actions of vitamin D in various immune‑related disorders: a comprehensive review . Front Immunol . 2023 ; 14 : 950465 .

Aibana O , Huang CC , Aboud S , Arnedo‑Pena A , Becerra MC , Bellido‑Blasco JB , et al . Vitamin D status and risk of incident tuberculosis disease: a nested case‑control study, systematic review, and individual‑participant data meta‑analysis . PLoS Med . 2019 ; 16 ( 9 ): e1002907 .

Shukla A , Bromage S , Dholakia Y , Hemler EC , Dev P , Govekar L , et al . Case‑control study of vitamin D status and adult multidrug‑resistant pulmonary TB . Int J Tuberc Lung Dis . 2022 ; 26 ( 9 ): 826 – 34 .

Tamara L , Kartasasmita CB , Alam A , Gurnida DA . Effects of vitamin D supplementation on resolution of fever and cough in children with pulmonary tuberculosis: a randomized double‑blind controlled trial in Indonesia . J Glob Health . 2022 ; 12 : 04015 .

Rekha RS , Mily A , Sultana T , Haq A , Ahmed S , Mostafa Kamal SM , et al . Immune responses in the treatment of drug‑sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D 3 as host directed therapy . BMC Infect Dis . 2018 ; 18 ( 1 ): 303 .

Salahuddin N , Ali F , Hasan Z , Rao N , Aqeel M , Mahmood F . Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT study [supplementary cholecalciferol in recovery from tuberculosis]. A randomized, placebo‑controlled, clinical trial of vitamin D supple‑mentation in patients with pulmonary tuberculosis . BMC Infect Dis . 2013 ; 13 : 22 .

Mily A , Rekha RS , Kamal SM , Arifuzzaman AS , Rahim Z , Khan L , et al . Significant effects of oral phenylbutyrate and vitamin D 3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial . PLoS One . 2015 ; 10 ( 9 ): e0138340 .

Ganmaa D , Munkhzul B , Fawzi W , Spiegelman D , Willett WC , Bayas‑galan P , et al . High‑dose vitamin D 3 during tuberculosis treatment in Mongolia. A randomized controlled trial . Am J Respir Crit Care Med . 2017 ; 196 ( 5 ): 628 – 37 .

Sudfeld CR , Mugusi F , Muhihi A , Aboud S , Nagu TJ , Ulenga N , et al . Effi‑cacy of vitamin D 3 supplementation for the prevention of pulmonary tuberculosis and mortality in HIV: a randomised, double‑blind, placebo‑controlled trial . Lancet HIV . 2020 ; 7 ( 7 ): e463 – 71 .

Ganmaa D , Uyanga B , Zhou X , Gantsetseg G , Delgerekh B , Enkhmaa D , et al . Vitamin D supplements for prevention of tuberculosis infection and disease . N Engl J Med . 2020 ; 383 ( 4 ): 359 – 68 .

Martineau AR , Wilkinson KA , Newton SM , Floto RA , Norman AW , Skolimowska K , et al . IFN‑γ‑ and TNF‑independent vitamin D‑inducible human suppression of mycobacteria: the role of cathelicidin IL‑37 . J Immunol . 2007 ; 178 ( 11 ): 7190 – 8 .

Yuk JM , Shin DM , Lee HM , Yang CS , Jin HS , Kim KK , et al . Vitamin D 3 induces autophagy in human monocytes/macrophages via cathelici‑din . Cell Host Microbe . 2009 ; 6 ( 3 ): 231 – 43 .

Coussens A , Timms PM , Boucher BJ , Venton TR , Ashcroft AT , Skoli‑mowska KH , et al . 1α, 25‑dihydroxy vitamin D 3 inhibits matrix metallo‑proteinases induced by Mycobacterium tuberculosis infection . Immunol‑ogy . 2009 ; 127 ( 4 ): 539 – 48 .

Lew MH , Norazmi MN , Nordin F , Tye GJ . A novel peptide vaccination augments cytotoxic CD8 + T‑cell responses against Mycobacterium tuberculosis HspX antigen . Immunobiology . 2022 ; 227 ( 3 ): 152201 .

Wang P , Wang L , Zhang W , Bai Y , Kang J , Hao Y , et al . Immunothera‑peutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B‑ESAT6 fusion protein against persistent tuberculosis infection in mice . Hum Vaccin Immunother . 2014 ; 10 ( 1 ): 150 – 8 .

Yi Z , Fu Y , Yang C , Li J , Luo X , Chen Q , et al . Recombinant M. smegmatis vaccine targeted delivering IL‑12/GLS into macrophages can induce specific cellular immunity against M. tuberculosis in BALB/c mice . Vac‑cine . 2007 ; 25 ( 4 ): 638 – 48 .

An Y , Ni R , Zhuang L , Yang L , Ye Z , Li L , et al . Tuberculosis vaccines and therapeutic drug: challenges and future directions . Mol Biomed . 2025 ; 6 ( 1 ): 4 .

Gong WP , Liang Y , Ling YB , Zhang JX , Yang YR , Wang L , et al . Effects of Mycobacterium vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes . Mil Med Res . 2020 ; 7 ( 1 ): 25 .

Rodríguez‑Güell E , Agustí G , Corominas M , Cardona PJ , Luquin M , Julián E . Mice with pulmonary tuberculosis treated with Mycobacterium vaccae develop strikingly enhanced recall gamma interferon responses to M. vaccae cell wall skeleton . Clin Vaccine Immunol . 2008 ; 15 ( 5 ): 893 – 6 .

Zhang L , Jiang Y , Cui Z , Yang W , Yue L , Ma Y , et al . Mycobacterium vaccae induces a strong Th1 response that subsequently declines in C57BL/6 mice . J Vet Sci . 2016 ; 17 ( 4 ): 505 – 13 .

Stanford JL , Bahr GM , Rook GA , Shaaban MA , Chugh TD , Gabriel M , et al . Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis . Tubercle . 1990 ; 71 ( 2 ): 87 – 93 .

Yang XY , Chen QF , Li YP , Wu SM . Mycobacterium vaccae as adjuvant therapy to anti‑tuberculosis chemotherapy in never‑treated tuberculo‑sis patients: a meta‑analysis . PLoS One . 2011 ; 6 ( 9 ): e23826 .

Weng H , Huang JY , Meng XY , Li S , Zhang GQ . Adjunctive therapy of Mycobacterium vaccae vaccine in the treatment of multidrug‑resistant tuberculosis: a systematic review and meta‑analysis . Biomed Rep . 2016 ; 4 ( 5 ): 595 – 600 .

Dhillon J , Mitchison DA . Effect of vaccines in a murine model of dor‑mant tuberculosis . Tuberc Lung Dis . 1994 ; 75 ( 1 ): 61 – 4 .

Gröschel MI , Prabowo SA , Cardona PJ , Stanford JL , van der Werf TS . Therapeutic vaccines for tuberculosis‑a systematic review . Vaccine . 2014 ; 32 ( 26 ): 3162 – 8 .

Rodríguez‑Güell E , Agustí G , Corominas M , Cardona PJ , Casals I , Parella T , et al . The production of a new extracellular putative long‑chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1‑cytokine production . Antonie Van Leeuwenhoek . 2006 ; 90 ( 1 ): 93 – 108 .

Das S , Chowdhury BP , Goswami A , Parveen S , Jawed J , Pal N , et al . Mycobacterium indicus pranii (MIP) mediated host protective intracel‑lular mechanisms against tuberculosis infection: involvement of TLR‑4 mediated signaling . Tuberculosis . 2016 ; 101 : 201 – 9 .

Zhou F , Zhang Y , Zhang D . Latest advances in the development of tuberculosis vaccines in global clinical trials: a review . Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi . 2024 ; 36 ( 2 ): 201 – 6 .

von Reyn CF , Lahey T , Arbeit RD , Landry B , Kailani L , Adams LV , et al . Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR‑901 . PLoS One . 2017 ; 12 ( 5 ): e0175215 .

Yong X , Xueqiong W . Expert consensus on immune function assess‑ment and immunotherapy in patients with active tuberculosis (2021 edition) . Zhongguo Fanglao Zazhi . 2022 ; 44 ( 1 ): 9 .

Masonou T , Hokey DA , Lahey T , Halliday A , Berrocal‑Almanza LC , Wieland‑Alter WF , et al . CD4 + T cell cytokine responses to the DAR‑901 booster vaccine in BCG‑primed adults: a randomized, placebo‑con‑trolled trial . PLoS One . 2019 ; 14 ( 5 ): e0217091 .

Prabowo SA , Painter H , Zelmer A , Smith SG , Seifert K , Amat M , et al . RUTI vaccination enhances inhibition of mycobacterial growth ex vivo and induces a shift of monocyte phenotype in mice . Front Immunol . 2019 ; 10 : 894 .

Cardona PJ , Amat I , Gordillo S , Arcos V , Guirado E , Díaz J , et al . Immuno‑therapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis . Vaccine . 2005 ; 23 ( 11 ): 1393 – 8 .

Gil O , Vilaplana C , Guirado E , Díaz J , Cáceres N , Singh M , et al . Enhanced gamma interferon responses of mouse spleen cells following immunotherapy for tuberculosis relapse . Clin Vaccine Immunol . 2008 ; 15 ( 11 ): 1742 – 4 .

Vilaplana C , Gil O , Cáceres N , Pinto S , Díaz J , Cardona PJ . Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis . PLoS One . 2011 ; 6 ( 5 ): e20404 .

Lange C , Aaby P , Behr MA , Donald PR , Kaufmann SHE , Netea MG , et al . 100 Years of Mycobacterium bovis Bacille Calmette‑Guérin . Lancet Infect Dis . 2022 ; 22 ( 1 ): e2 – 12 .

Valentini D , Rao M , Rane L , Rahman S , Axelsson‑Robertson R , Heuchel R , et al . Peptide microarray‑based characterization of antibody responses to host proteins after Bacille Calmette‑Guérin vaccination . Int J Infect Dis . 2017 ; 56 : 140 – 54 .

Singh AK , Srikrishna G , Bivalacqua TJ , Bishai WR . Recombinant BCGs for tuberculosis and bladder cancer . Vaccine . 2021 ; 39 ( 50 ): 7321 – 31 .

Yuan X , Teng X , Jing Y , Ma J , Tian M , Yu Q , et al . A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection . Appl Microbiol Biotechnol . 2015 ; 99 ( 24 ): 10587 – 95 .

Kowalewicz‑Kulbat M , Locht C . Recombinant BCG to enhance its immu‑nomodulatory activities . Vaccines . 2022 ; 10 ( 5 ): 827 .

Trentini MM , Kanno AI , Rodriguez D , Marques‑Neto LM , Eto SF , Chudzinki‑Tavassi AM , et al . Recombinant BCG expressing the LTAK63 adjuvant improves a short‑term chemotherapy schedule in the control of tuberculosis in mice . Front Immunol . 2022 ; 13 : 943558 .

Chiwala G , Liu Z , Mugweru JN , Wang B , Khan SA , Bate PNN , et al . A recombinant selective drug‑resistant M. bovis BCG enhances the bactericidal activity of a second‑line anti‑tuberculosis regimen . Biomed Pharmacother . 2021 ; 142 : 112047 .

Schrager LK , Vekemens J , Drager N , Lewinsohn DM , Olesen OF . The status of tuberculosis vaccine development . Lancet Infect Dis . 2020 ; 20 ( 3 ): e28 – 37 .

Sun Q , Li S , Gao M , Pang Y . Therapeutic strategies for tuberculosis: progress and lessons learned . Biomed Environ Sci . 2024 ; 37 ( 11 ): 1310 – 23 .

Penn‑Nicholson A , Tameris M , Smit E , Day TA , Musvosvi M , Jayashankar L , et al . Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA‑SE in BCG‑vaccinated healthy adults in South Africa: a ran‑domised, double‑blind, placebo‑controlled phase 1 trial . Lancet Respir Med . 2018 ; 6 ( 4 ): 287 – 98 .

Aagaard C , Hoang T , Dietrich J , Cardona PJ , Izzo A , Dolganov G , et al . A multistage tuberculosis vaccine that confers efficient protection before and after exposure . Nat Med . 2011 ; 17 ( 2 ): 189 – 94 .

Lin PL , Dietrich J , Tan E , Abalos RM , Burgos J , Bigbee C , et al . The mul‑tistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection . J Clin Investig . 2012 ; 122 ( 1 ): 303 – 14 .

McCann N , O’Connor D , Lambe T , Pollard AJ . Viral vector vaccines . Curr Opin Immunol . 2022 ; 77 : 102210 .

van Zyl‑Smit RN , Esmail A , Bateman ME , Dawson R , Goldin J , van Rikx‑oort E , et al . Safety and immunogenicity of adenovirus 35 tuberculosis vaccine candidate in adults with active or previous tuberculosis. A rand‑omized trial . Am J Respir Crit Care Med . 2017 ; 195 ( 9 ): 1171 – 80 .

Nyendak M , Swarbrick GM , Duncan A , Cansler M , Huff EW , Hokey D , et al . Adenovirally‑induced polyfunctional t cells do not necessarily rec‑ognize the infected target: lessons from a phase I trial of the AERAS‑402 vaccine . Sci Rep . 2016 ; 6 : 36355 .

Alyahya SA , Nolan ST , Smith CM , Bishai WR , Sadoff J , Lamichhane G . Immunogenicity without efficacy of an adenoviral tuberculosis vaccine in a stringent mouse model for immunotherapy during treatment . PLoS One . 2015 ; 10 ( 5 ): e0127907 .

Leung‑Theung‑Long S , Coupet CA , Gouanvic M , Schmitt D , Ray A , Hoffmann C , et al . A multi‑antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis . PLoS One . 2018 ; 13 ( 5 ): e0196815 .

Afkhami S , Lai R , D’Agostino MR , Vaseghi‑Shanjani M , Zganiacz A , Yao Y , et al . Single‑dose mucosal immunotherapy with chimpanzee adenovi‑rus‑based vaccine accelerates tuberculosis disease control and limits its rebound after antibiotic cessation . J Infect Dis . 2019 ; 220 ( 8 ): 1355 – 66 .

Melo A , de Macêdo LS , Invenção M , de Moura IA , da Gama M , de Melo CML , et al . Third‑generation vaccines: features of nucleic acid vaccines and strategies to improve their efficiency . Genes (Basel) . 2022 ; 13 ( 12 ): 2287 .

Qin F , Xia F , Chen H , Cui B , Feng Y , Zhang P , et al . A guide to nucleic acid vaccines in the prevention and treatment of infectious diseases and cancers: from basic principles to current applications . Front Cell Dev Biol . 2021 ; 9 : 633776 .

Mobed A . DNA based vaccines against Mycobacterium tuberculosis : recent progress in vaccine development and delivery system . Iran J Immunol . 2020 ; 17 ( 4 ): 255 – 74 .

Liang Y , Zhang X , Bai X , Xiao L , Wang X , Zhang J , et al . Immunogenicity and therapeutic effects of a Mycobacterium tuberculosis rv2190c DNA vaccine in mice . BMC Immunol . 2017 ; 18 ( 1 ): 11 .

Liang Y , Zhang X , Bai X , Yang Y , Gong W , Wang T , et al . Immunogenicity and therapeutic effects of latency‑associated genes in a Mycobacterium tuberculosis reactivation mouse model . Hum Gene Ther Methods . 2019 ; 30 ( 2 ): 60 – 9 .

Liang Y , Zhao Y , Bai X , Xiao L , Yang Y , Zhang J , et al . Immunotherapeutic effects of Mycobacterium tuberculosis RV3407 DNA vaccine in mice . Autoimmunity . 2018 ; 51 ( 8 ): 417 – 22 .

Tang J , Cai Y , Liang J , Tan Z , Tang X , Zhang C , et al . In vivo electropora‑tion of a codon‑optimized BER opt DNA vaccine protects mice from pathogenic Mycobacterium tuberculosis aerosol challenge . Tuberculosis . 2018 ; 113 : 65 – 75 .

Liang Y , Wu X , Zhang J , Xiao L , Yang Y , Bai X , et al . Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected with Mycobacterium tuberculosis . FEMS Immunol Med Microbiol . 2012 ; 66 ( 3 ): 419 – 26 .

Chauhan P , Jain R , Dey B , Tyagi AK . Adjunctive immunotherapy with α‑crystallin based DNA vaccination reduces tuberculosis chemotherapy period in chronically infected mice . Sci Rep . 2013 ; 3 : 1821 .

Lowrie DB , Tascon RE , Bonato VL , Lima VM , Faccioli LH , Stavropoulos E , et al . Therapy of tuberculosis in mice by DNA vaccination . Nature . 1999 ; 400 ( 6741 ): 269 – 71 .

Reljic R , Paul MJ , Arias MA . Cytokine therapy of tuberculosis at the crossroads . Expert Rev Respir Med . 2009 ; 3 ( 1 ): 53 – 66 .

Hu XD , Chen ST , Yu DH , Li SX , Cai H . Immunotherapy with combined DNA vaccines is an effective treatment for M. bovis infection in cattle . Vaccine . 2009 ; 27 ( 9 ): 1317 – 22 .

Zárate‑Bladés CR , Bonato VLD , da Silveira ELV , Oliveira e Paula M , Junta CM , Sandrin‑Garcia P , et al . Comprehensive gene expression profiling in lungs of mice infected with Mycobacterium tuberculosis following DNAhsp65 immunotherapy . J Gene Med . 2009 ; 11 ( 1 ): 66 – 78 .

Rodrigues RF , Zárate‑Bladés CR , Rios WM , Soares LS , Souza PR , Brandão IT , et al . Synergy of chemotherapy and immunotherapy revealed by a genome‑scale analysis of murine tuberculosis . J Antimicrob Chem‑other . 2015 ; 70 ( 6 ): 1774 – 83 .

Karanika S , Gordy JT , Neupane P , Karantanos T , Ruelas Castillo J , Quijada D , et al . An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis . Front Immunol . 2022 ; 13 : 972266 .

Yu DH , Hu XD , Cai H . Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT‑64 and MPT‑83 . Gene Ther . 2008 ; 15 ( 9 ): 652 – 9 .

Doimo NTS , Zárate‑Bladés CR , Rodrigues RF , Tefé‑Silva C , Trotte MN , Souza PR , et al . Immunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross‑reactive antibodies against mammalian Hsp60 but not pathological autoimmunity . Hum Vaccin Immunother . 2014 ; 10 ( 5 ): 1238 – 43 .

Linares‑Fernández S , Lacroix C , Exposito JY , Verrier B . Tailoring mrna vaccine to balance innate/adaptive immune response . Trends Mol Med . 2020 ; 26 ( 3 ): 311 – 23 .

Deng M , Wang X , Xiong Z , Tang P . Control of RNA degradation in cell fate decision . Front Cell Dev Biol . 2023 ; 11 : 1164546 .

Zheng C , Zhang L . Identifying RNA sensors in antiviral innate immunity . Methods Mol Biol . 2025 ; 2854 : 107 – 15 .

Xue T , Stavropoulos E , Yang M , Ragno S , Vordermeier M , Chambers M , et al . RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection . Infect Immun . 2004 ; 72 ( 11 ): 6324 – 9 .

Al Tbeishat H . Novel in silico mRNA vaccine design exploiting proteins of M. tuberculosis that modulates host immune responses by inducing epigenetic modifications . Sci Rep . 2022 ; 12 ( 1 ): 4645 .

Shahrear S , Islam A . Modeling of MT. P495, an mRNA‑based vaccine against the phosphate‑binding protein PstS1 of Mycobacterium tuberculosis . Mol Divers . 2023 ; 27 ( 4 ): 1613 – 32 .

Dougé A , Caux C , Bay JO . Cell therapy in all its forms . Bull Cancer . 2024 ; 111 ( 2 ): 213 – 21 .

Rao M , Ligeiro D , Maeurer M . Precision medicine in the clinical man‑agement of respiratory tract infections including multidrug‑resistant tuberculosis: learning from innovations in immuno‑oncology . Curr Opin Pulm Med . 2019 ; 25 ( 3 ): 233 – 41 .

Wang Z , Cao YJ . Adoptive cell therapy targeting neoantigens: a frontier for cancer research . Front Immunol . 2020 ; 11 : 176 .

Patel S , Lang H , Sani G , Freeman AF , Leiding J , Hanley PJ , et al . Myco‑bacteria‑specific T cells may be expanded from healthy donors and are near absent in primary immunodeficiency disorders . Front Immunol . 2019 ; 10 : 621 .

Zhou CY , Wen Q , Chen XJ , Wang RN , He WT , Zhang SM , et al . Human CD8 + T cells transduced with an additional receptor bispecific for both Mycobacterium tuberculosis and HIV‑1 recognize both epitopes . J Cell Mol Med . 2016 ; 20 ( 10 ): 1984 – 98 .

Zhou CY , Wang RN , Wen Q , He WT , Zhang SM , Du XL , et al . Alanine mutagenesis in the complementarity determining region 3 of the MTB and HIV‑1 peptide‑bispecific T cell receptor beta chain affects ligand recognition . Front Immunol . 2017 ; 8 : 983 .

Zhou CY , Wang RN , He WT , Luo DR , Yuan SR , Wen Q , et al . Functional analysis of the antigen binding sites on the MTB/HIV‑1 peptide bispe‑cific T‑cell receptor complementarity determining region 3α . AIDS . 2023 ; 37 ( 1 ): 33 – 42 .

Chen CY , Yao S , Huang D , Wei H , Sicard H , Zeng G , et al . Phosphoan‑tigen/IL2 expansion and differentiation of Vγ2Vδ2 T cells increase resistance to tuberculosis in nonhuman primates . PLoS Pathog . 2013 ; 9 ( 8 ): e1003501 .

Orme IM , Collins FM . Adoptive protection of the Mycobacterium tuberculosis ‑infected lung. Dissociation between cells that passively transfer protective immunity and those that transfer delayed‑type hypersensitivity to tuberculin . Cell Immunol . 1984 ; 84 ( 1 ): 113 – 20 .

Orme IM . An age‑related loss of the isogeneic barrier to the successful passive cell transfer of antimicrobial immunity in mice . Mech Ageing Dev . 1988 ; 46 ( 1–3 ): 29 – 32 .

Khan A , Mann L , Papanna R , Lyu MA , Singh CR , Olson S , et al . Mes‑enchymal stem cells internalize Mycobacterium tuberculosis through scavenger receptors and restrict bacterial growth through autophagy . Sci Rep . 2017 ; 7 ( 1 ): 15010 .

Suresh K , Naidoo J , Lin CT , Danoff S . Immune checkpoint immunother‑apy for non‑small cell lung cancer: benefits and pulmonary toxicities . Chest . 2018 ; 154 ( 6 ): 1416 – 23 .

Luo YC , Huang XT , Wang R , Lin YJ , Sun JX , Li KF , et al . Advancements in understanding tumor‑resident bacteria and their application in cancer therapy . Mil Med Res . 2025 ; 12 ( 1 ): 38 .

Lyu M , Xu G , Zhou J , Reboud J , Wang Y , Lai H , et al . Single‑cell sequenc‑ing reveals functional alterations in tuberculosis . Adv Sci (Weinh) . 2024 ; 11 ( 11 ): e2305592 .

Ishida Y . PD‑1: its discovery, involvement in cancer immunotherapy, and beyond . Cells . 2020 ; 9 ( 6 ): 1376 .

Okazaki T , Maeda A , Nishimura H , Kurosaki T , Honjo T . PD‑1 immuno‑receptor inhibits B cell receptor‑mediated signaling by recruiting src homology 2‑domain‑containing tyrosine phosphatase 2 to phosphoty‑rosine . Proc Natl Acad Sci U S A . 2001 ; 98 ( 24 ): 13866 – 71 .

Gao M , Shi J , Xiao X , Yao Y , Chen X , Wang B , et al . PD‑1 regula‑tion in immune homeostasis and immunotherapy . Cancer Lett . 2024 ; 588 : 216726 .

Sheppard KA , Fitz LJ , Lee JM , Benander C , George JA , Wooters J , et al . PD‑1 inhibits T‑cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ . FEBS Lett . 2004 ; 574 ( 1–3 ): 37 – 41 .

Freeman GJ , Long AJ , Iwai Y , Bourque K , Chernova T , Nishimura H , et al . Engagement of the PD‑1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation . J Exp Med . 2000 ; 192 ( 7 ): 1027 – 34 .

Bagchi S , Yuan R , Engleman EG . Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance . Annu Rev Pathol . 2021 ; 16 : 223 – 49 .

Marasco M , Berteotti A , Weyershaeuser J , Thorausch N , Sikorska J , Krausze J , et al . Molecular mechanism of SHP2 activation by PD‑1 stimulation . Sci Adv . 2020 ; 6 ( 5 ): eaay4458 .

Hui E , Cheung J , Zhu J , Su X , Taylor MJ , Wallweber HA , et al . T cell costimulatory receptor CD28 is a primary target for PD‑1‑mediated inhibition . Science . 2017 ; 355 ( 6332 ): 1428 – 33 .

Tousif S , Singh Y , Prasad DV , Sharma P , Van Kaer L , Das G . T cells from programmed death‑1 deficient mice respond poorly to Mycobacterium tuberculosis infection . PLoS One . 2011 ; 6 ( 5 ): e19864 .

Butte MJ , Keir ME , Phamduy TB , Sharpe AH , Freeman GJ . Programmed death‑1 ligand 1 interacts specifically with the B7‑1 costimulatory molecule to inhibit T cell responses . Immunity . 2007 ; 27 ( 1 ): 111 – 22 .

Zhu C , Anderson AC , Kuchroo VK . TIM‑3 and its regulatory role in immune responses . Curr Top Microbiol Immunol . 2011 ; 350 : 1 – 15 .

Sada‑Ovalle I , Ocaña‑Guzman R , Pérez‑Patrigeón S , Chávez‑Galán L , Sierra‑Madero J , Torre‑Bouscoulet L , et al . Tim‑3 blocking rescue macrophage and T cell function against Mycobacterium tuberculosis infection in HIV + patients . J Int AIDS Soc . 2015 ; 18 ( 1 ): 20078 .

Jayaraman P , Sada‑Ovalle I , Beladi S , Anderson AC , Dardalhon V , Hotta C , et al . Tim3 binding to galectin‑9 stimulates antimicrobial immunity . J Exp Med . 2010 ; 207 ( 11 ): 2343 – 54 .

Manzoor A , Barakat K . Therapeutic potential of TIM‑3 inhibition in can‑cer, viral infections, and autoimmune disorders . Int J Biochem Cell Biol . 2025 ; 186 : 106826 .

Zhao L , Cheng S , Fan L , Zhang B , Xu S . TIM‑3: an update on immuno‑therapy . Int Immunopharmacol . 2021 ; 99 : 107933 .

Ferrara R , Imbimbo M , Malouf R , Paget‑Bailly S , Calais F , Marchal C , et al . Single or combined immune checkpoint inhibitors compared to first‑line platinum‑based chemotherapy with or without bevacizumab for people with advanced non‑small cell lung cancer . Cochrane Database Syst Rev . 2021 ; 4 ( 4 ): Cd013257 .

Pan J , Zhang X , Xu J , Chang Z , Xin Z , Wang G . Landscape of exhausted T cells in tuberculosis revealed by single‑cell sequencing . Microbiol Spectr . 2023 ; 11 ( 2 ): e0283922 .

Wang LL , Janes ME , Kumbhojkar N , Kapate N , Clegg JR , Prakash S , et al . Cell therapies in the clinic . Bioeng Transl Med . 2021 ; 6 ( 2 ): e10214 .

Han F , Lu P . Future challenges and perspectives for stem cell therapy of neurodegenerative diseases . Adv Exp Med Biol . 2020 ; 1266 : 141 – 5 .

Abreu TR , Fonseca NA , Gonçalves N , Moreira JN . Current challenges and emerging opportunities of CAR‑T cell therapies . J Control Release . 2020 ; 319 : 246 – 61 .

Wang Z , Liu X , Cao F , Bellanti JA , Zhou J , Zheng SG . Prospects of the use of cell therapy to induce immune tolerance . Front Immunol . 2020 ; 11 : 792 .

Langan EA , Graetz V , Allerheiligen J , Zillikens D , Rupp J , Terheyden P . Immune checkpoint inhibitors and tuberculosis: an old disease in a new context . Lancet Oncol . 2020 ; 21 ( 1 ): e55 – 65 .

Fujita K , Yamamoto Y , Kanai O , Okamura M , Hashimoto M , Nakatani K , et al . Incidence of active tuberculosis in lung cancer patients receiving immune checkpoint inhibitors . Open Forum Infect Dis . 2020 ; 7 ( 5 ): ofaa126 .

Riudavets M , Wyplosz B , Ghigna MR , Botticella A , Abdayem P , Pradere P , et al . Complete remission after immunotherapy‑induced abdominal tuberculosis in a patient with advanced NSCLC treated with pembroli‑zumab: a case report . JTO Clin Res Rep . 2022 ; 3 ( 5 ): 100319 .

Lee JJX , Chan A , Tang T . Tuberculosis reactivation in a patient receiving anti‑programmed death‑1 (PD‑1) inhibitor for relapsed Hodgkin’s lymphoma . Acta Oncol . 2016 ; 55 ( 4 ): 519 – 20 .

Fujita K , Terashima T , Mio T . Anti‑PD1 antibody treatment and the development of acute pulmonary tuberculosis . J Thorac Oncol . 2016 ; 11 ( 12 ): 2238 – 40 .

Chu YC , Fang KC , Chen HC , Yeh YC , Tseng CE , Chou TY , et al . Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti‑PD‑1 treatment in a patient with advanced pulmonary adenocarcinoma . J Thorac Oncol . 2017 ; 12 ( 8 ): e111 – 4 .

Picchi H , Mateus C , Chouaid C , Besse B , Marabelle A , Michot JM , et al . Infectious complications associated with the use of immune check‑point inhibitors in oncology: reactivation of tuberculosis after anti PD‑1 treatment . Clin Microbiol Infect . 2018 ; 24 ( 3 ): 216 – 8 .

Chan GH , Gwee YX , Low JL , Huang Y , Chan ZY , Choo JR , et al . Immune checkpoint inhibition for non‑small cell lung cancer in patients with pulmonary tuberculosis or hepatitis B: experience from a single Asian centre . Lung Cancer‑J Iaslc . 2020 ; 146 : 145 – 53 .

Chen HW , Kuo YW , Chen CY , Chang CH , Wang SM , Chien YC , et al . Increased tuberculosis reactivation risk in patients receiving immune checkpoint inhibitor‑based therapy . Oncologist . 2024 ; 29 ( 4 ): e498 – 506 .

Anand K , Sahu G , Burns E , Ensor A , Ensor J , Pingali SR , et al . Mycobacte‑rial infections due to PD‑1 and PD‑L1 checkpoint inhibitors . ESMO Open . 2020 ; 5 ( 4 ): e000866 .

Mootoo A , Stylianou E , Arias MA , Reljic R . TNF‑α in tuberculosis: a cytokine with a split personality . Inflamm Allergy Drug Targets . 2009 ; 8 ( 1 ): 53 – 62 .

Tezera LB , Bielecka MK , Ogongo P , Walker NF , Ellis M , Garay‑Baquero DJ , et al . Anti‑PD‑1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF‑α . Elife . 2020 ; 9 : e52668 .

Korotych O , Achar J , Gurbanova E , Hovhannesyan A , Lomtadze N , Ciobanu A , et al . Effectiveness and safety of modified fully oral 9‑month treatment regimens for rifampicin‑resistant tuberculosis: a prospective cohort study . Lancet Infect Dis . 2024 ; 24 ( 10 ): 1151 – 61 .

Zhang H , Liu L , Hu J , Wu X , Zheng J , Xin H , et al . Transcriptomic and proteomic signatures of host NK cells delineate distinct immune states across tuberculosis infection statuses . Front Immunol . 2025 ; 16 : 1607770 .